05798375 is referenced by 19 patents and cites 41 patents.

A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-�1-(4-2'-pyridylphenyl)ethylideneaminooxy!-ethoxy}benzyl)thiazolid ine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo�5,4-b!pyridin-2-yl-methoxy)benzyl}thiazoli dine-2,4-dione or its hydrochloride, 5-�4-(6-methoxy-l-methylbenzimidazol-2-ylmethoxy)benzyl!thiazolidine-2,4-d ione, 5-�4-(l-methylbenzimidazol-2-ylmethoxy)benzyl!-thiazolidine-2,4-dione and 5-�4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy) benzyllthiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

Title
Treatment of arteriosclerosis and xanthoma
Application Number
8/676090
Publication Number
5798375
Application Date
July 2, 1996
Publication Date
August 25, 1998
Inventor
Takashi Ito
Kobe
JP
Hiroyoshi Horikoshi
Kobe
JP
Yoshio Tsujita
Tokyo
JP
Agent
Frishauf Holtz Goodman Langer & Chick Esq
Assignee
Sankyo Company
JP
IPC
A61K 31/21
A61K 31/425
View Original Source